AZD9150 (Danvatirsen), an antisense oligonucleotide inhibitor of STAT3 mRNA expression, is being investigated in a clinical trial (NCT03421353) for patients with advanced solid tumors, including NSCLC, either alone or in combination with chemotherapy. Here, STAT3 is linked to non-small cell lung carcinoma.